Estrella Immunopharma completes first dose cohort in STARLIGHT-1; DSMB approves second dose

Estrella Immunopharma, Inc.

First cohort enrolled relapsed/refractory B-cell NHL patients who failed multiple prior therapies; no DLTs or SAEs.
DSMB approved escalation to second cohort at 5 million receptor-positive T cells/kg of EB103 therapy.
Preliminary data showed tumor responses in all patients at Month 1; favorable safety profile.
STARLIGHT-1 is an open-label, multi-center 3+3 dose-escalation study to determine RP2D for EB103.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.